Selwood
Andrew G. Selwood, Berkshire GB
Patent application number | Description | Published |
---|---|---|
20140041060 | Keypad Device - An example tamper detection mechanism may include an electrical pathway having a closed conductive configuration and being openable to prevent electrical conduction along the electrical pathway, and may further include detection circuitry connected to the electrical pathway and configured to detect a change in the resistance of the electrical pathway. The electrical pathway includes a pair of conductive pads electrically isolated from one another, and also includes a connector which in the closed conductive configuration contacts both conductive pads to form an electrical connection therebetween. The connector is moveable away from the pads to open the electrical connection for tamper detection. The connector has a resistor of predefined resistance which in the closed conductive configuration is included in the electrical pathway. The detection circuitry can distinguish, on the basis of the resistance of the electrical pathway, between connection of the pads by the connector and shorting between the two pads. | 02-06-2014 |
Andrew George Selwood, Reading GB
Patent application number | Description | Published |
---|---|---|
20100238040 | MECHANISM FOR DETECTING SEPARATION OF A COMPONENT FROM A PART AND A COMPONENT CARRYING SUCH A MECHANISM - A component ( | 09-23-2010 |
Andrew George Selwood, Berkshire GB
Patent application number | Description | Published |
---|---|---|
20120009826 | CIRCUIT BOARD CONNECTOR WITH DRILLING TAMPER DETECTION ARRANGEMENT - A connector ( | 01-12-2012 |
Andrew Ian Selwood, Nelson NZ
Patent application number | Description | Published |
---|---|---|
20120108526 | ANTI-MICROBIAL COMPOSITIONS - Antimicrobial compounds from | 05-03-2012 |
20140357580 | ANTI-MICROBIAL COMPOSITIONS - Antimicrobial compounds from | 12-04-2014 |
David Selwood, Welwyn Garden City GB
Patent application number | Description | Published |
---|---|---|
20160002299 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS - A cyclosporin derivative which is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a viral infection: wherein: A represents (F(II)) or (F(III)) B represents methyl or ethyl, R | 01-07-2016 |
David Selwood, Hertfordshire GB
Patent application number | Description | Published |
---|---|---|
20120101301 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS - The present invention relates to a process for preparing a compound of formula wherein: R | 04-26-2012 |
David Selwood, London GB
Patent application number | Description | Published |
---|---|---|
20080260756 | Peptide Inhibitors of iASPP - The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide. | 10-23-2008 |
20080262011 | Modulator - The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R | 10-23-2008 |
20100022525 | Arginine Derivatives with NP-I Antagonistic Activity - The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists. | 01-28-2010 |
20100144876 | MODULATOR - The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR | 06-10-2010 |
20120077863 | GUANIDINO-SUBSTITUTED BI-AND POLYPHENYLS AS SMALL MOLECULE CARRIERS - A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein —X | 03-29-2012 |
20120122862 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY - The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists. | 05-17-2012 |
20120157385 | CYCLOSPORIN CONJUGATES - A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R | 06-21-2012 |
20120201749 | NP-1 Antagonists and Their Therapeutic Use - Compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein: W is arylene, heteroarylene or formula (a) each L is independently alkylene, alkenylene, alkynylene, a direct bond, arylene, cycloalkylene, alkylene-arylene, alkylene-C═O or —C═O; each X is independently an N-containing heteroarylene, N-containing cycloalkylene or NR; Y is N-containing heteroaryl, N-containing cycloalkyl, NR | 08-09-2012 |
20120269864 | Arginine Derivatives with NP-I Antagonistic Activity - The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists. | 10-25-2012 |
20120283295 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS - The invention provides an indazole derivative of formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein R | 11-08-2012 |
20130123356 | MODULATOR - The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, | 05-16-2013 |
20140357569 | CYCLOSPORIN CONJUGATES - A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R | 12-04-2014 |
20150353476 | CRYSTALLINE FORM OF VSN16 - The present invention relates to a compound of formula (I) in crystalline form, wherein said compound is in the form of the free base or a pharmaceutically acceptable salt thereof, or a solvate of the free base or salt form thereof. The invention also relates to a pharmaceutical composition containing said crystalline form as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline form. | 12-10-2015 |
David Lawrence Selwood, London GB
Patent application number | Description | Published |
---|---|---|
20090069331 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH - Compounds of formula (I) have been found to be useful as inhibitors of DDAH. The present invention thus provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disease whose pathology is affected by DDAH | 03-12-2009 |
Tobias J. Selwood, London GB
Patent application number | Description | Published |
---|---|---|
20090125878 | System and Method for Generating Modified Source Code Based on Change-Models - A computer implemented method for automatically generating domain specific applications based on model driven changes of the source code base for existing applications. Abstracted declarative design change-models, separate from detailed implementation source coding, are used to define the possible set of changes for specific application domains. Generalized implementations of the design changes, mapped to the defined Change-Model abstracted representations but separate from the representations themselves, are implemented via Application-Templates consisting of existing source code plus mark-up. The application domain is thus defined by the change-model linked to allied application-templates. Meta generation facilities are implicitly provided as the code generator for a specific application domain is defined by the Change-Model plus related set of Application-Templates. Additionally, the generator GUI is automatically modified or generated from the Change-Model with optional GUI model extensions definitions to tailor the generator GUI for each specific application domain. | 05-14-2009 |